…A double-blind, placebo-controlled study in Austria reports that nutritional supplementation with omega-3 polyunsaturated fatty acid (PUFA) reduces progression to first-episode psychotic disorder in high-risk individuals (Amminger et al. Arch Gen Psychiatry 2010; 67: 146-154). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…Low-dose topiramate appears to be as effective as the atypical antipsychotic agent risperidone in controlling behavioural disturbances in AD patients, according to the results of a double-blind trial (Mowla & Pani. J Clin Psychopharmacol 2010; 30: 40-43). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…the newsletter with Continue…
View commentary by Daniel Selchen, MD Following news reports last fall of a possible cure for MS, clinicians and MS Societies worldwide have been inundated with inquiries about the new procedure. Its originator, Dr. Paulo Zamboni of Ferrara, Italy, has reported that a condition that he calls chronic cerebrospinal venous insufficiency (CCSVI) is the underlying problem in multiple sclerosis. Subscribe to read more It takes 30 seconds or login using…
A group in the U.K. has published a consensus statement on the use of the atypical antipsychotic aripiprazole for acute mania (Aitchison et al. J Psychopharmacol 2009; 23: 231-240). Unlike other atypical antipsychotic agents (clozapine, risperidone, olanzapine, quetiapine, ziprasidone), aripiprazole acts as a partial agonist at the dopamine D2 and serotonin 5HT-1A and 5HT-2C receptors, and as a 5HT-2A antagonist (for a recent review see Pae CU. E…